XML 59 R27.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Segments of business and geographic areas | 12 Months Ended
--- | ---
Dec. 31, 2023
Segment Reporting [Abstract] |
Segments of business and geographic areas | Segments of business and geographic areas Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two business segments: Innovative Medicine (formerly referred to as Pharmaceutical) and MedTech. The segment results have been recast for all periods to reflect the continuing operations of the Company.
|  | Sales to Customers |  | % Change
(Dollars in Millions) |  | 2023 |  | 2022 |  | 2021 |  | ’23 vs. ’22 |  | ’22 vs. ’21
INNOVATIVE MEDICINE(1) |  |  |  |  |  |  |  |  |  |
Immunology |  |  |  |  |  |  |  |  |  |
U.S. |  | $11,539 |  | 11,036 |  | 10,843 |  | 4.6 | % |  | 1.8 |
International |  | 6,513 |  | 5,899 |  | 5,907 |  | 10.4 |  |  | (0.1) |
Worldwide |  | 18,052 |  | 16,935 |  | 16,750 |  | 6.6 |  |  | 1.1 |
REMICADE |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,143 |  | 1,417 |  | 2,019 |  | (19.3) |  |  | (29.8) |
U.S. Exports |  | 147 |  | 204 |  | 236 |  | (28.0) |  |  | (13.6) |
International |  | 549 |  | 722 |  | 935 |  | (23.9) |  |  | (22.8) |
Worldwide |  | 1,839 |  | 2,343 |  | 3,190 |  | (21.5) |  |  | (26.6) |
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,124 |  | 1,166 |  | 1,127 |  | (3.6) |  |  | 3.5 |
International |  | 1,073 |  | 1,017 |  | 1,148 |  | 5.4 |  |  | (11.4) |
Worldwide |  | 2,197 |  | 2,184 |  | 2,276 |  | 0.6 |  |  | (4.0) |
STELARA |  |  |  |  |  |  |  |  |  |
U.S. |  | 6,966 |  | 6,388 |  | 5,938 |  | 9.0 |  |  | 7.6 |
International |  | 3,892 |  | 3,335 |  | 3,196 |  | 16.7 |  |  | 4.4 |
Worldwide |  | 10,858 |  | 9,723 |  | 9,134 |  | 11.7 |  |  | 6.5 |
TREMFYA |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,147 |  | 1,844 |  | 1,503 |  | 16.5 |  |  | 22.7 |
International |  | 999 |  | 824 |  | 624 |  | 21.2 |  |  | 32.0 |
Worldwide |  | 3,147 |  | 2,668 |  | 2,127 |  | 17.9 |  |  | 25.4 |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |
U.S. |  | 11 |  | 17 |  | 21 |  | (33.8) |  |  | (18.4) |
International |  | 0 |  | 0 |  | 3 |  | — |  |  | *
Worldwide |  | 11 |  | 17 |  | 24 |  | (33.8) |  |  | (28.2) |
Infectious Diseases |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,500 |  | 1,680 |  | 2,249 |  | (10.7) |  |  | (25.3) |
International |  | 2,918 |  | 3,769 |  | 3,576 |  | (22.6) |  |  | 5.4 |
Worldwide |  | 4,418 |  | 5,449 |  | 5,825 |  | (18.9) |  |  | (6.5) |
COVID-19 VACCINE |  |  |  |  |  |  |  |  |  |
U.S. |  | 0 |  | 120 |  | 634 |  | * |  | (81.1) |
International |  | 1,117 |  | 2,059 |  | 1,751 |  | (45.8) |  |  | 17.6 |
Worldwide |  | 1,117 |  | 2,179 |  | 2,385 |  | (48.8) |  |  | (8.6) |
|  | Sales to Customers |  | % Change
(Dollars in Millions) |  | 2023 |  | 2022 |  | 2021 |  | ’23 vs. ’22 |  | ’22 vs. ’21
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |
U.S. |  | 35 |  | 36 |  | 41 |  | (3.7) |  |  | (10.8) |
International |  | 1,115 |  | 972 |  | 953 |  | 14.8 |  |  | 2.0 |
Worldwide |  | 1,150 |  | 1,008 |  | 994 |  | 14.1 |  |  | 1.5 |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,446 |  | 1,494 |  | 1,508 |  | (3.2) |  |  | (1.0) |
International |  | 408 |  | 449 |  | 575 |  | (9.2) |  |  | (21.9) |
Worldwide |  | 1,854 |  | 1,943 |  | 2,083 |  | (4.6) |  |  | (6.7) |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |
U.S. |  | 19 |  | 30 |  | 66 |  | (34.5) |  |  | (55.5) |
International |  | 278 |  | 289 |  | 297 |  | (3.8) |  |  | (2.6) |
Worldwide |  | 297 |  | 318 |  | 363 |  | (6.7) |  |  | (12.3) |
Neuroscience |  |  |  |  |  |  |  |  |  |
U.S. |  | 4,065 |  | 3,570 |  | 3,347 |  | 13.9 |  |  | 6.7 |
International |  | 3,076 |  | 3,323 |  | 3,641 |  | (7.5) |  |  | (8.7) |
Worldwide |  | 7,140 |  | 6,893 |  | 6,988 |  | 3.6 |  |  | (1.4) |
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |
U.S. |  | 230 |  | 151 |  | 172 |  | 52.5 |  |  | (12.5) |
International |  | 554 |  | 493 |  | 495 |  | 12.2 |  |  | (0.4) |
Worldwide |  | 783 |  | 644 |  | 667 |  | 21.6 |  |  | (3.5) |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,897 |  | 2,714 |  | 2,550 |  | 6.7 |  |  | 6.5 |
International |  | 1,218 |  | 1,426 |  | 1,472 |  | (14.6) |  |  | (3.1) |
Worldwide |  | 4,115 |  | 4,140 |  | 4,022 |  | (0.6) |  |  | 3.0 |
SPRAVATO |  |  |  |  |  |  |  |  |  |
U.S. |  | 589 |  | 328 |  | 198 |  | 79.7 |  |  | 65.7 |
International |  | 100 |  | 46 |  | 26 |  | * |  | 76.9 |
Worldwide |  | 689 |  | 374 |  | 224 |  | 84.1 |  |  | 67.0 |
OTHER NEUROSCIENCE(2) |  |  |  |  |  |  |  |  |  |
U.S. |  | 349 |  | 376 |  | 427 |  | (7.3) |  |  | (11.9) |
International |  | 1,204 |  | 1,358 |  | 1,647 |  | (11.3) |  |  | (17.5) |
Worldwide |  | 1,553 |  | 1,734 |  | 2,074 |  | (10.4) |  |  | (16.4) |
Oncology |  |  |  |  |  |  |  |  |  |
U.S. |  | 8,462 |  | 6,930 |  | 5,958 |  | 22.1 |  |  | 16.3 |
International |  | 9,199 |  | 9,052 |  | 8,590 |  | 1.6 |  |  | 5.4 |
Worldwide |  | 17,661 |  | 15,983 |  | 14,548 |  | 10.5 |  |  | 9.9 |
|  | Sales to Customers |  | % Change
(Dollars in Millions) |  | 2023 |  | 2022 |  | 2021 |  | ’23 vs. ’22 |  | ’22 vs. ’21
CARVYKTI |  |  |  |  |  |  |  |  |  |
U.S. |  | 469 |  | 133 |  | — |  | * |  | *
International |  | 30 |  | — |  | — |  | * |  | *
Worldwide |  | 500 |  | 133 |  | — |  | * |  | *
DARZALEX |  |  |  |  |  |  |  |  |  |
U.S. |  | 5,277 |  | 4,210 |  | 3,169 |  | 25.4 |  |  | 32.8 |
International |  | 4,467 |  | 3,767 |  | 2,854 |  | 18.6 |  |  | 32.0 |
Worldwide |  | 9,744 |  | 7,977 |  | 6,023 |  | 22.2 |  |  | 32.4 |
ERLEADA |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,065 |  | 968 |  | 813 |  | 10.0 |  |  | 19.2 |
International |  | 1,322 |  | 913 |  | 478 |  | 44.8 |  |  | *
Worldwide |  | 2,387 |  | 1,881 |  | 1,291 |  | 26.9 |  |  | 45.7 |
IMBRUVICA |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,051 |  | 1,390 |  | 1,747 |  | (24.4) |  |  | (20.4) |
International |  | 2,214 |  | 2,394 |  | 2,622 |  | (7.5) |  |  | (8.7) |
Worldwide |  | 3,264 |  | 3,784 |  | 4,369 |  | (13.7) |  |  | (13.4) |
ZYTIGA /abiraterone acetate |  |  |  |  |  |  |  |  |  |
U.S. |  | 50 |  | 74 |  | 119 |  | (32.1) |  |  | (37.8) |
International |  | 837 |  | 1,696 |  | 2,178 |  | (50.7) |  |  | (22.1) |
Worldwide |  | 887 |  | 1,770 |  | 2,297 |  | (49.9) |  |  | (22.9) |
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |
U.S. |  | 549 |  | 156 |  | 110 |  | * |  | 41.8 |
International |  | 330 |  | 283 |  | 458 |  | 16.9 |  |  | (38.2) |
Worldwide |  | 879 |  | 438 |  | 568 |  | * |  | (22.9) |
Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,697 |  | 2,346 |  | 2,365 |  | 15.0 |  |  | (0.8) |
International |  | 1,117 |  | 1,071 |  | 1,085 |  | 4.3 |  |  | (1.3) |
Worldwide |  | 3,815 |  | 3,417 |  | 3,450 |  | 11.6 |  |  | (1.0) |
OPSUMIT |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,292 |  | 1,132 |  | 1,147 |  | 14.1 |  |  | (1.3) |
International |  | 681 |  | 651 |  | 672 |  | 4.6 |  |  | (3.2) |
Worldwide |  | 1,973 |  | 1,783 |  | 1,819 |  | 10.6 |  |  | (2.0) |
UPTRAVI |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,326 |  | 1,104 |  | 1,056 |  | 20.1 |  |  | 4.5 |
International |  | 255 |  | 218 |  | 181 |  | 17.3 |  |  | 20.4 |
Worldwide |  | 1,582 |  | 1,322 |  | 1,237 |  | 19.7 |  |  | 6.9 |
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |
U.S. |  | 79 |  | 110 |  | 163 |  | (28.6) |  |  | (32.3) |
International |  | 182 |  | 202 |  | 232 |  | (10.3) |  |  | (12.8) |
Worldwide |  | 260 |  | 313 |  | 395 |  | (16.7) |  |  | (20.8) |
|  | Sales to Customers |  | % Change
(Dollars in Millions) |  | 2023 |  | 2022 |  | 2021 |  | ’23 vs. ’22 |  | ’22 vs. ’21
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,906 |  | 3,042 |  | 3,192 |  | (4.5) |  |  | (4.7) |
International |  | 765 |  | 845 |  | 927 |  | (9.4) |  |  | (8.9) |
Worldwide |  | 3,671 |  | 3,887 |  | 4,119 |  | (5.5) |  |  | (5.6) |
XARELTO |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,365 |  | 2,473 |  | 2,438 |  | (4.4) |  |  | 1.4 |
International |  | — |  | — |  | — |  | — |  |  | — |
Worldwide |  | 2,365 |  | 2,473 |  | 2,438 |  | (4.4) |  |  | 1.4 |
OTHER(3) |  |  |  |  |  |  |  |  |  |
U.S. |  | 541 |  | 569 |  | 754 |  | (5.0) |  |  | (24.5) |
International |  | 765 |  | 845 |  | 927 |  | (9.4) |  |  | (8.8) |
Worldwide |  | 1,306 |  | 1,414 |  | 1,682 |  | (7.6) |  |  | (15.9) |
TOTAL INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |
U.S. |  | 31,169 |  | 28,604 |  | 27,954 |  | 9.0 |  |  | 2.3 |
International |  | 23,590 |  | 23,959 |  | 23,726 |  | (1.5) |  |  | 1.0 |
Worldwide |  | 54,759 |  | 52,563 |  | 51,680 |  | 4.2 |  |  | 1.7 |
MEDTECH |  |  |  |  |  |  |  |  |  |
Interventional Solutions |  |  |  |  |  |  |  |  |  |
U.S. |  | 3,633 |  | 2,169 |  | 1,836 |  | 67.5 |  |  | 18.2 |
International |  | 2,717 |  | 2,131 |  | 2,135 |  | 27.5 |  |  | (0.2) |
Worldwide |  | 6,350 |  | 4,300 |  | 3,971 |  | 47.7 |  |  | 8.3 |
ELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,458 |  | 2,036 |  | 1,730 |  | 20.7 |  |  | 17.7 |
International |  | 2,230 |  | 1,901 |  | 1,893 |  | 17.3 |  |  | 0.4 |
Worldwide |  | 4,688 |  | 3,937 |  | 3,623 |  | 19.1 |  |  | 8.7 |
ABIOMED(4) |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,066 |  | 31 |  | — |  | * |  | *
International |  | 240 |  | — |  | — |  | * |  | *
Worldwide |  | 1,306 |  | 31 |  | — |  | * |  | *
OTHER INTERVENTIONAL SOLUTIONS |  |  |  |  |  |  |  |  |  |
U.S. |  | 109 |  | 102 |  | 106 |  | 6.7 |  |  | (3.8) |
International |  | 247 |  | 230 |  | 242 |  | 7.3 |  |  | (5.0) |
Worldwide |  | 356 |  | 332 |  | 348 |  | 7.1 |  |  | (4.6) |
Orthopaedics |  |  |  |  |  |  |  |  |  |
U.S. |  | 5,525 |  | 5,321 |  | 5,126 |  | 3.8 |  |  | 3.8 |
International |  | 3,417 |  | 3,267 |  | 3,462 |  | 4.6 |  |  | (5.6) |
Worldwide |  | 8,942 |  | 8,587 |  | 8,588 |  | 4.1 |  |  | 0.0 |
HIPS |  |  |  |  |  |  |  |  |  |
U.S. |  | 996 |  | 943 |  | 878 |  | 5.6 |  |  | 7.3 |
International |  | 564 |  | 571 |  | 602 |  | (1.2) |  |  | (5.1) |
Worldwide |  | 1,560 |  | 1,514 |  | 1,480 |  | 3.0 |  |  | 2.3 |
|  | Sales to Customers |  | % Change
(Dollars in Millions) |  | 2023 |  | 2022 |  | 2021 |  | ’23 vs. ’22 |  | ’22 vs. ’21
KNEES |  |  |  |  |  |  |  |  |  |
U.S. |  | 896 |  | 851 |  | 787 |  | 5.3 |  |  | 8.2 |
International |  | 559 |  | 508 |  | 538 |  | 10.2 |  |  | (5.7) |
Worldwide |  | 1,456 |  | 1,359 |  | 1,325 |  | 7.1 |  |  | 2.6 |
TRAUMA |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,949 |  | 1,882 |  | 1,819 |  | 3.6 |  |  | 3.5 |
International |  | 1,030 |  | 989 |  | 1,066 |  | 4.1 |  |  | (7.2) |
Worldwide |  | 2,979 |  | 2,871 |  | 2,885 |  | 3.8 |  |  | (0.5) |
SPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,684 |  | 1,645 |  | 1,642 |  | 2.4 |  |  | 0.2 |
International |  | 1,263 |  | 1,198 |  | 1,256 |  | 5.4 |  |  | (4.6) |
Worldwide |  | 2,947 |  | 2,843 |  | 2,898 |  | 3.7 |  |  | (1.9) |
Surgery |  |  |  |  |  |  |  |  |  |
U.S. |  | 4,031 |  | 3,897 |  | 3,867 |  | 3.4 |  |  | 0.8 |
International |  | 6,006 |  | 5,793 |  | 5,945 |  | 3.7 |  |  | (2.6) |
Worldwide |  | 10,037 |  | 9,690 |  | 9,812 |  | 3.6 |  |  | (1.2) |
ADVANCED |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,833 |  | 1,784 |  | 1,761 |  | 2.8 |  |  | 1.3 |
International |  | 2,837 |  | 2,785 |  | 2,861 |  | 1.9 |  |  | (2.6) |
Worldwide |  | 4,671 |  | 4,569 |  | 4,622 |  | 2.2 |  |  | (1.1) |
GENERAL |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,198 |  | 2,113 |  | 2,105 |  | 4.0 |  |  | 0.4 |
International |  | 3,168 |  | 3,008 |  | 3,085 |  | 5.3 |  |  | (2.5) |
Worldwide |  | 5,366 |  | 5,121 |  | 5,190 |  | 4.8 |  |  | (1.3) |
Vision |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,086 |  | 1,990 |  | 1,857 |  | 4.8 |  |  | 7.2 |
International |  | 2,986 |  | 2,859 |  | 2,831 |  | 4.5 |  |  | 1.0 |
Worldwide |  | 5,072 |  | 4,849 |  | 4,688 |  | 4.6 |  |  | 3.4 |
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,626 |  | 1,522 |  | 1,398 |  | 6.8 |  |  | 8.9 |
International |  | 2,076 |  | 2,022 |  | 2,043 |  | 2.7 |  |  | (1.0) |
Worldwide |  | 3,702 |  | 3,543 |  | 3,440 |  | 4.5 |  |  | 3.0 |
SURGICAL |  |  |  |  |  |  |  |  |  |
U.S. |  | 460 |  | 468 |  | 459 |  | (1.8) |  |  | 2.0 |
International |  | 910 |  | 837 |  | 788 |  | 8.6 |  |  | 6.2 |
Worldwide |  | 1,370 |  | 1,306 |  | 1,248 |  | 4.9 |  |  | 4.6 |
TOTAL MEDTECH |  |  |  |  |  |  |  |  |  |
U.S. |  | 15,275 |  | 13,377 |  | 12,686 |  | 14.2 |  |  | 5.4 |
International |  | 15,125 |  | 14,050 |  | 14,374 |  | 7.7 |  |  | (2.3) |
Worldwide |  | 30,400 |  | 27,427 |  | 27,060 |  | 10.8 |  |  | 1.4 |
|  | Sales to Customers |  | % Change
(Dollars in Millions) |  | 2023 |  | 2022 |  | 2021 |  | ’23 vs. ’22 |  | ’22 vs. ’21
WORLDWIDE |  |  |  |  |  |  |  |  |  |
U.S. |  | 46,444 |  | 41,981 |  | 40,640 |  | 10.6 |  |  | 3.3 |
International |  | 38,715 |  | 38,009 |  | 38,100 |  | 1.9 |  |  | (0.2) |
Worldwide |  | $85,159 |  | 79,990 |  | 78,740 |  | 6.5 | % |  | 1.6 |
*Percentage greater than 100% or not meaningful (1)Previously referred to as Pharmaceutical (2)Inclusive of RISPERDAL CONSTA which was previously disclosed separately (3) Inclusive of INVOKANA which was previously disclosed separately (4) Acquired on December 22, 2022
|  | Income Before Tax |  | Identifiable Assets
(Dollars in Millions) |  | 2023 (3) |  | 2022 (4) |  | 2021 (5) |  | 2023 |  | 2022
Innovative Medicine |  | $18,246 |  | 15,647 |  | 17,750 |  | $58,324 |  | 58,436
MedTech |  | 4,669 |  | 4,447 |  | 4,208 |  | 74,710 |  | 70,956
Total |  | 22,915 |  | 20,094 |  | 21,958 |  | 133,034 |  | 129,392
Less: Expense not allocated to segments (1) |  | 7,853 |  | 735 |  | 2,780 |  |  |  |
Discontinued operations |  |  |  |  |  |  |  | — |  | 27,237
General corporate (2) |  |  |  |  |  |  |  | 34,524 |  | 30,749
Worldwide total |  | $15,062 |  | 19,359 |  | 19,178 |  | $167,558 |  | 187,378
|  | Additions to Property, Plant & Equipment |  | Depreciation and Amortization
(Dollars in Millions) |  | 2023 |  | 2022 |  | 2021 |  | 2023 |  | 2022 |  | 2021
Innovative Medicine |  | $1,653 |  | 1,374 |  | 1,198 |  | $3,847 |  | 3,687 |  | 4,029
MedTech |  | 2,372 |  | 2,120 |  | 1,933 |  | 2,943 |  | 2,302 |  | 2,286
Segments total |  | 4,025 |  | 3,494 |  | 3,131 |  | 6,790 |  | 5,989 |  | 6,315
Discontinued operations |  | 162 |  | 303 |  | 314 |  | 383 |  | 641 |  | 739
General corporate |  | 356 |  | 212 |  | 207 |  | 313 |  | 340 |  | 336
Worldwide total |  | $4,543 |  | 4,009 |  | 3,652 |  | $7,486 |  | 6,970 |  | 7,390
|  | Sales to Customers |  | Long-Lived Assets (6)
(Dollars in Millions) |  | 2023 |  | 2022 |  | 2021 |  | 2023 |  | 2022
United States |  | $46,444 |  | 41,981 |  | 40,640 |  | $54,832 |  | 58,750
Europe |  | 20,410 |  | 20,664 |  | 20,595 |  | 31,616 |  | 29,878
Western Hemisphere excluding U.S. |  | 4,549 |  | 4,108 |  | 3,927 |  | 1,491 |  | 1,289
Asia-Pacific, Africa |  | 13,756 |  | 13,237 |  | 13,578 |  | 1,500 |  | 1,520
Segments total |  | 85,159 |  | 79,990 |  | 78,740 |  | 89,439 |  | 91,437
Discontinued operations |  |  |  |  |  |  |  | — |  | 27,237
General corporate |  |  |  |  |  |  |  | 1,192 |  | 1,081
Other non long-lived assets |  |  |  |  |  |  |  | 76,927 |  | 67,623
Worldwide total |  | $85,159 |  | 79,990 |  | 78,740 |  | $167,558 |  | 187,378
See Note 1 for a description of the segments in which the Company operates. Export sales are not significant. In fiscal year 2023, the Company utilized three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total consolidated revenues. In fiscal year 2022, the Company had three wholesalers distributing products for both segments that represented approximately 18.9%, 15.0% and 13.8% of the total consolidated revenues. In fiscal year 2021, the Company had three wholesalers distributing products for all three segments that represented approximately 16.6%, 12.6%, and 12.6% of the total consolidated revenues. (1)Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. Fiscal 2023 includes an approximately $7 billion charge related to talc matters (See Note 19, Legal proceedings, for additional details) and $0.4 billion related to the unfavorable change in the fair value of the retained stake in Kenvue. (2)General corporate includes cash, cash equivalents and marketable securities. (3)Innovative Medicine includes: •One-time COVID-19 Vaccine manufacturing exit related costs of $0.7 billion •A restructuring related charge of $0.5 billion •Unfavorable changes in the fair value of securities of $0.4 billion •Favorable litigation related items of $0.1 billion •Loss on divestiture $0.2 billion. •An intangible asset impairment charge of approximately $0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020. MedTech includes: •Acquired in process research and development asset of $0.4 billion related to the Laminar acquisition in 2023 •A restructuring related charge of $0.3 billion •Acquisition and integration related costs of $0.2 billion primarily related to the acquisition of Abiomed •A Medical Device Regulation charge of $0.3 billion •Income from litigation settlements of $0.1 billion (4)Innovative Medicine includes: •One-time COVID-19 Vaccine manufacturing exit related costs of $1.5 billion •An intangible asset impairment charge of approximately $0.8 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS •Litigation expense of $0.1 billion •Unfavorable changes in the fair value of securities of $0.7 billion •A restructuring related charge of $0.1 billion MedTech includes: •Litigation expense of $0.6 billion primarily for pelvic mesh related costs •A restructuring related charge of $0.3 billion •Acquisition and integration related costs of $0.3 billion primarily related to the acquisition of Abiomed •A Medical Device Regulation charge of $0.3 billion (5)Innovative Medicine includes: •Litigation expense of $0.6 billion, primarily related to Risperdal Gynecomastia •Divestiture gains of $0.6 billion •Gains of $0.5 billion related to the change in the fair value of securities •A restructuring related charge of $0.1 billion MedTech includes: •An in-process research and development expense of $0.9 billion related to Ottava •A restructuring related charge of $0.3 billion •A Medical Device Regulation charge of $0.2 billion •Litigation expense of $0.1 billion (6)Long-lived assets include property, plant and equipment, net for fiscal years 2023, and 2022 of $19,898 and $17,982, respectively, and intangible assets and goodwill, net for fiscal years 2023 and 2022 of $70,733 and $74,536, respectively.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContent Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration